Dispersal of synaptic mGluR1 clusters by Aβ requires NMDAR and VDCC activity. by Francesco Roselli (211670)

“…MK alone; 109.8±4.1%, for verapamil+Aβ vs. verapamil alone). (C, D) Aβ treatment results in decreased synaptic localization of total mGluR1 (ratio of mGluR1/synaptophysin immunopositive puncta, 47.3±5.7% of baseline, n = 600, p<0.05); pre-treatment with either MK801 or verapamil prevented this effect (102.0±7.2%, for MK801+Aβ vs. …”

Supplementary Material for: Effects of liquid and bar soaps on the skin of Brazilian newborns: a randomized controlled trial by Ramos M.C.M. (17825624)

“…Introduction: Compared to adults, newborns’ skin has thinner epidermis and stratum corneum with decreased hydration level, higher transepidermal water loss, and pH variation between 5.5 and 7.5. …”

Synthesis, Properties, and Reactions of a Series of Stable Dialkyl-Substituted Silicon−Chalcogen Doubly Bonded Compounds by Takeaki Iwamoto (1391731)

<b>Evaluating Trauma-Focused Cognitive Behavioral Therapy in Earthquake Survivors: A Controlled Trial</b> by Metin Çınaroğlu (18498525)

“…Assessments were conducted using the PTSD Checklist (PCL), Beck Depression Inventory-II (BDI-II), and Beck Anxiety Inventory (BAI) at baseline, after the sixth and twelfth sessions, and at a three-month follow-up. Results showed substantial improvements in the treatment group, with PTSD scores decreasing from an average of 37.5 to 20.4, depression scores from 31.5 to 24.2, and anxiety scores from 31.5 to 24.2. …”

Synthesis, Properties, and Reactions of a Series of Stable Dialkyl-Substituted Silicon−Chalcogen Doubly Bonded Compounds by Takeaki Iwamoto (1391731)

Supplementary Material for: A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Oral Administration of a Heat-Treated <b><i>Lactobacillus paracasei  </i></b>Suppleme... by Yan D.-C. (6724247)

Supplementary Material for: The efficacy of hemoperfusion in severe COVID-19 patients: A systematic review and meta-analysis by figshare admin karger (2628495)

“…The hemoperfusion (HP) group had a longer length of stay compared with the control group (WMD 5.25[2.53, 7.97]days; p < 0.05; I2 = 28.0%), but not the ICU stay (ES 1.33[-2.86, 5.53]days; p = 0.53; I2 = 85.5%). …”

Table_1_Can a Multi-Component Intervention Improve Pediatric Service Delivery in Guangzhou?.DOCX by Fang Hu (476414)

“…The average efficiency of pediatric service fluctuated from 2010 to 2019. A unit increase in PPTC was associated with an 11% reduction in IMR and a 16% reduction in U5MR.…”

A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity-3 by Denise A Gonzales (38545)

“…<p><b>Copyright information:</b></p><p>Taken from "A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity"</p><p>http://www.biomedcentral.com/1741-7015/5/32</p><p>BMC Medicine 2007;5():32-32.…”

Data Sheet 1_Polyphenol-mediated microbiome modulation in STEMI patients: a pilot study.zip by Argul Issilbayeva (21398168)

“…</p>Conclusion<p>Our findings demonstrate that polyphenol supplementation maintains stable TMAO levels by restructuring gut microbiome composition in STEMI patients, evidenced by a more focused microbiome with a significant increase in beneficial butyrate-producing bacteria (Roseburia, Agathobaculum sp., Alistipes finegoldii, and Sellimonas) and a decreased Firmicutes/Bacteroidetes ratio, suggesting microbiome-mediated cardioprotective effects. …”

Supplementary Material for: Opioid and Other Medication Use and General Health Status in a Cohort of Older Adults by Pinsky P.F. (10280336)

“…<b><i>Methods:</i></b> Among participants in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening Trial linked to Medicare Part D claims data and answering a quality-of-life questionnaire, we examined the relationship between medication use over a 5-year period and various self-reported health status variables assessed several years later, including overall health status (STATUS) and trouble with activities of daily living (TADL). …”

Influence on number of top-ups after implementing patient controlled epidural analgesia: A cohort study by Ganapathy van Samkar (813139)

“…(<i>p</i> = 0.0001) Sedation tended to occur more frequently in patients with CEA versus PCEA, 5.5% vs 1.6% (<i>p</i> = 0.05). Implementation of PCEA led to a decreased number of top-ups, fewer side-effects and decreased use of the postoperative care unit.…”

Pumping H⁺ or Na⁺ does not offer a sustained selective advantage. by Víctor Sojo (613931)

“…<p>(A) Pumping H⁺ in a membrane with 1% ATPase causes a sustained loss in −ΔG as membrane permeability decreases with 1% pump. …”

Thrombolysis in Acute Ischemic Stroke: A Simulation Study to Improve Pre- and in-Hospital Delays in Community Hospitals by Maarten M. H. Lahr (486176)

“…The aim of this simulation study was to assess the impact of previously identified success factors in a central model on thrombolysis rates and patient outcome when implemented for a decentral model.…”

<i>CDKN3</i> mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer by Eira Valeria Barrón (796117)

“…<i>CDKN3</i> mRNA was measured in 134 CC and 25 controls by quantitative PCR. A 5-year survival study was conducted in 121 of these CC patients. …”

Table 1_Evaluation of a multi-epitope vaccine PME for Pasteurella multocida in mouse model.docx by Rui Zhang (13940)

“…The protection rates of His-PME group and pcDNA3.1-PME group were 62.5% and 75% against P. multocida serotype A, and 87.5% and 100% against P. multocida serotype D, respectively. …”

Age at treatment initiation–cross sex hormones. by Lucy Thompson (3705940)

“…Puberty suppression (PS) was generally induced with Gonadotropin Releasing Hormone analogues (GnRHa), and at a pooled mean age of 14.5 (±1.0) years. Cross Sex Hormone (CSH) therapy was initiated at a pooled mean of 16.2 (±1.0) years. …”

Study characteristics. by Lucy Thompson (3705940)

“…Puberty suppression (PS) was generally induced with Gonadotropin Releasing Hormone analogues (GnRHa), and at a pooled mean age of 14.5 (±1.0) years. Cross Sex Hormone (CSH) therapy was initiated at a pooled mean of 16.2 (±1.0) years. …”

Age at treatment initiation–puberty suppression. by Lucy Thompson (3705940)

“…Puberty suppression (PS) was generally induced with Gonadotropin Releasing Hormone analogues (GnRHa), and at a pooled mean age of 14.5 (±1.0) years. Cross Sex Hormone (CSH) therapy was initiated at a pooled mean of 16.2 (±1.0) years. …”

Search terms. by Lucy Thompson (3705940)

“…Puberty suppression (PS) was generally induced with Gonadotropin Releasing Hormone analogues (GnRHa), and at a pooled mean age of 14.5 (±1.0) years. Cross Sex Hormone (CSH) therapy was initiated at a pooled mean of 16.2 (±1.0) years. …”